Zhejiang Hisun Pharmaceutical Co., Ltd. Class ASSE: 600267

Announcement on HS387 Tablets Obtaining the U.S. FDA Approval for Clinical Trials of a New Drug

· Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on HS387 Tablets Obtaining the U.S. FDA Approval for Clinical Trials of a New Drug

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis